Selected Publications

Academic Article

Year Title Altmetric
2019 Confidence in Women's Health: A Cross Border Survey of Adult Nephrologists.Journal of Clinical Medicine.  8. 2019
2019 CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.American Journal of Kidney Diseases.  73:218-229. 2019
2018 Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.Kidney International Reports.  3:1373-1384. 2018
2018 Secondary IgA nephropathy.Kidney International.  94:674-681. 2018
2018 Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients.BioTechniques.  65:71-77. 2018
2018 Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes.European Journal of Nuclear Medicine.  45:1998-2008. 2018
2018 A Novel Method for Rapid Bedside Measurement of GFR.Journal of the American Society of Nephrology.  29:1609-1613. 2018
2018 Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.PLoS ONE.  13:e0190967. 2018
2017 Prognostic value of silent myocardial infarction in patients with chronic kidney disease being evaluated for kidney transplantation.International Journal of Cardiology.  249:377-382. 2017
2016 The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.Frontiers in Immunology.  7:117. 2016
2015 Migrated intra-jejunal peritoneal dialysis catheter.Kidney International.  88:1457. 2015
2015 Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.Circulation.  132:27-39. 2015
2015 Oral anticoagulants and risk of nephropathy.Drug Safety.  38:527-533. 2015
2015 The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.Clinical Journal of the American Society of Nephrology.  10:791-799. 2015
2015 New Insights into the Pathogenesis of IgA Nephropathy.Kidney Diseases.  1:8-18. 2015
2015 Screening for coronary artery disease in kidney transplant candidates.Journal of Nuclear Cardiology.  22:297-300. 2015
2015 A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).Nephron.  130:159-168. 2015
2014 Dietary patterns and risk of death and progression to ESRD in individuals with CKD: a cohort study.American Journal of Kidney Diseases.  64:204-213. 2014
2014 The interdisciplinary team: the whole is larger than the parts.Advances in Renal Replacement Therapy.  21:333-337. 2014
2013 Renovascular hypertension associated with pseudoaneurysm following blunt trauma.American Journal of Kidney Diseases.  62:839-843. 2013
2013 Bullous Lesions After Use of a Commercial Therapeutic Hypothermia Temperature Management System: A Possible Burn Injury?Therapeutic Hypothermia and Temperature Management.  3:147-150. 2013
2013 Association between urinary albumin excretion and coronary heart disease in black vs white adults.Journal of the American Medical Association.  310:706-714. 2013
2013 Cardiovascular risk factors in CKD associate with both ESRD and mortality.Journal of the American Society of Nephrology.  24:1159-1165. 2013
2013 Association of duration of residence in the southeastern United States with chronic kidney disease may differ by race: the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.International Journal of Health Geographics.  12:17. 2013
2013 Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseNew England Journal of Medicine.  369:2492-2503. 2013
2013 Cardioprotective medication use and risk factor control among US adults with unrecognized myocardial infarction: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.Vascular Health and Risk Management.  9:47-55. 2013
2012 Racial differences in albuminuria, kidney function, and risk of stroke.Neurology.  79:1686-1692. 2012
2012 Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease.Nephrology Dialysis Transplantation.  27:3482-3488. 2012
2012 Kidney disease education one year after the Medicare Improvement of Patients and Providers Act: a survey of US nephrology practices.American Journal of Kidney Diseases.  59:892-894. 2012
2011 Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality.Clinical Journal of the American Society of Nephrology.  6:2200-2207. 2011
2011 Warfarin-related nephropathy: another newly recognized complication of an old drug.Kidney International.  80:131-133. 2011
2009 Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.Clinical Journal of the American Society of Nephrology.  4:560-566. 2009
2008 Gadolinium nephrotoxicity: Case report of a rare entity and review of the literatureClinical Nephrology.  70:518-522. 2008
2008 Gadolinium nephrotoxicity: case report of a rare entity and review of the literature.Clinical Nephrology.  70:518-522. 2008
2008 Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.Pediatric Nephrology.  23:1029-1036. 2008
2004 Medullary cystic kidney disease type 2.American Journal of Kidney Diseases.  43:1142. 2004
2003 Cystic and inherited kidney diseases.American Journal of Kidney Diseases.  42:1305-1317. 2003


Year Title Altmetric
2013 Polycystic and other cystic kidney diseases.  362-370. 2013

Research Overview

  • IgA nephropathy
  • Principal Investigator On

  • Private Grant  awarded by ACHILLION PHARMACEUTICALS INC 2018 - 2022
  • Private Grant  awarded by REATA PHARMACEUTICALS 2018 - 2022
  • Private Grant  awarded by REATA PHARMACEUTICALS 2017 - 2020
  • Private Grant  awarded by ABBVIE INC 2015 - 2018
  • A Randomized Controlled Trial of Rituximub versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)  awarded by MAYO CLINIC 2013 - 2018
  • Private Grant  awarded by FAST BIOMEDICAL 2017
  • Private Grant  awarded by NEPHROGENEX, INC. 2015 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by FAST BIOMEDICAL 2013 - 2014
  • Private Grant  awarded by REATA PHARMACEUTICALS 2011 - 2013
  • Private Grant  awarded by REATA PHARMACEUTICALS 2012
  • Private Grant  awarded by AMGEN, INC. 2007 - 2012
  • Private Grant  awarded by REATA PHARMACEUTICALS 2009 - 2010
  • Education And Training

  • Doctor of Medicine, Foreign University
  • St. Louis University Hospitals, Internship 1999
  • American University of Beirut Medical Center, Internship 1998
  • Emory University Hospital Systems, Residency 2001
  • St. Louis University Hospitals, Residency 2000
  • Emory University Hospital Systems, Postdoctoral Fellowship 2005
  • Full Name

  • Dana Rizk